# Human Immunomics & Trained Immunity in Persistent Candidemia

> **NIH NIH U19** · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · 2024 · $449,138

## Abstract

PROJECT SUMMARY
Hematologic disseminated candidiasis (HDC) is the most common invasive fungal species in hospital settings
worldwide. The mortality rate is high (40%) for these infections despite treatment with antifungal therapies.
Similarly, methicillin-resistant strains of Staphylococcus aureus (MRSA) can cause invasive and life-threatening
infections despite treatment with standard anti-infective therapies. Thus, persistence reflects host-pathogen
interactions occurring uniquely in context of antibiotic therapy in vivo. However, host factors and mechanisms
involved in persistent MRSA and HDC remain unclear. This study will use systems-based, high-throughput
multi-omics platforms and novel statistical and computational approaches to provide a comprehensive
longitudinal assessment of host in vitro and in vivo innate and adaptive responses to HDC and MRSA infection
using patient peripheral blood, stimulus specific PAMPs and patient-derived HDC plasma PAMPs and isolates.
Innovative deliverables include: i) Constructing an in-depth immune profile of HDC and MRSA immune profiles;
ii) understand the stimulus-specificity of de novo enhancer formation in macrophages and how they affect
transcriptional landscapes and functions iii) generate a detailed molecular map of the cross-talk between the
innate and adaptive immune response during HDC and MRSA infection; iv) using the combination of
biostatistics and computational modeling to explain and predict cellular and molecular networks driving trained
immunity and persistent, resolving, and survival outcomes; and v) identification and validation of druggable
epigenomic regulators of reprogramming. Detailed insights into the interaction of HDC and MRSA with the host
immune system stand to generate fundamentally new mechanistic hypotheses and diagnostic tools to guide
development of therapeutic strategies.

## Key facts

- **NIH application ID:** 10904651
- **Project number:** 5U19AI172713-02
- **Recipient organization:** LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
- **Principal Investigator:** ELAINE F REED
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $449,138
- **Award type:** 5
- **Project period:** 2023-08-10 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10904651

## Citation

> US National Institutes of Health, RePORTER application 10904651, Human Immunomics & Trained Immunity in Persistent Candidemia (5U19AI172713-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10904651. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*